Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,365 recruiting cancer studies with a site in New York — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
New York, New YorkAges 18 years+ - NCT07037758RecruitingPhase 1
Study of tarlatamab and AB248 for extensive stage small cell lung cancer
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
New York, New YorkAges 18–90 - NCT06825715Recruiting
Precision oncology support for lung and prostate cancer
This study tests a program to help veterans with lung or prostate cancer get personalized cancer treatments. The goal is to see if extra support for doctors and patients leads to better use of precision medicine.
New York, New YorkAges Any age - NCT06565260Recruiting
Exercise and nutrition program for cancer survivors and caregivers
This study offers a community-based program of exercise and nutrition classes for cancer survivors and their caregivers. It aims to help improve health and well-being after cancer treatment.
Buffalo, New YorkAges 18 years+ - NCT06535867Recruiting
Comparing phone-based vs. in-person mouth cancer screening in rural India
This study compares two ways to find early signs of mouth cancer or conditions that could lead to cancer. One method uses a simple phone-based health check, and the other uses standard in-person screening. People in rural areas of Varanasi who are at risk—such as those who use tobacco or have mouth sores—may be able to join.
New York, New YorkAges 18 years+ - NCT06312124Recruiting
Fallopian tube removal to prevent ovarian cancer
This study looks at removing fallopian tubes during other planned surgeries to help prevent ovarian cancer. You may be able to join if you are at least 45 years old, are female or assigned female at birth, and are having non-gynecologic surgery (like gallbladder or hernia repair).
Uniondale, New YorkAges 45 years+ - NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
North Hills, New YorkAges 18 years+ - NCT04712877Recruiting
Blood and tumor testing to choose the right lung cancer treatment
This trial tests tumor tissue and a blood sample to help doctors pick the most personalized treatment for people with suspected lung cancer. It may help ensure you get therapy matched to your specific tumor characteristics, especially when the cancer might be surgically removed.
New York, New YorkAges Any age - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+ - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
New York, New YorkAges 18 years+ - NCT04696575RecruitingPhase 2
Lamivudine added to chemoimmunotherapy for extensive-stage lung cancer
This trial tests whether adding lamivudine to standard chemoimmunotherapy can improve outcomes for people with extensive-stage small cell lung cancer. It aims to see if this combination controls the cancer better than standard treatment alone.
Buffalo, New YorkAges 18 years+ - NCT03547973RecruitingPhase 2
Study of sacituzumab govitecan for advanced or non-removable bladder cancer
This trial tests sacituzumab govitecan, an anti-cancer drug, for people with urothelial (bladder/urinary tract) cancer that has spread or can’t be removed with surgery. It’s designed for tumors that have been treated already in specific ways, to see if the medicine can shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT05354570RecruitingPhase 2
Radiation for thymic cancer that has spread to lung lining
This Phase 2 study tests a precise type of chest radiation that targets cancer in the lung lining (pleura) while trying to protect healthy lungs and organs. It may help people with thymic cancer that has spread to the pleura, including cases that return after prior treatment.
Rockville Centre, New YorkAges 18–79 - NCT05121051RecruitingPhase 2
Broccoli sprout extract to reduce tobacco cancer-causing chemicals
This Phase 2 study tests whether broccoli sprout extract (Avmacol ES) can reduce cancer-causing substances linked to heavy smoking. It’s for adults who smoke heavily and may help lower harmful tobacco-related chemical effects in the body.
Buffalo, New YorkAges 18 years+ - NCT05420064Recruiting
Help with family cancer gene testing and unclear results
This trial helps people and their doctors understand and act on genetic test results, including when results are uncertain. It tests whether a structured approach improves who gets tested in families and helps patients and primary care providers stay up-to-date.
New York, New YorkAges 25 years+ - NCT04402788RecruitingPhase 2/Phase 3
Radiation added to immune therapy for extensive small cell lung cancer
This trial tests whether adding radiation therapy to standard immune therapy (atezolizumab) after initial chemo can help people with extensive-stage small cell lung cancer live longer and control the cancer better. You must have a good response (partial response) or stable disease after initial treatment, plus several lab/imaging checks to confirm safety.
Camillus, New YorkAges 18 years+ - NCT03396341Recruiting
Surveys after genetic risk results for certain breast cancer genes
This study asks women to complete surveys after learning their genetic risk results for certain breast cancer–related gene changes. It helps researchers understand how people respond and what they think or feel after getting these results.
Commack, New YorkAges 25 years+ - NCT06079671RecruitingPhase 3
Volrustomig for high-risk locally advanced cervical cancer
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
New York, New YorkAges 15 years+ - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Long Island City, New YorkAges 18 years+ - NCT05818683RecruitingPhase 1
Pasritamig plus other drugs for advanced prostate cancer
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
Brooklyn, New YorkAges 18 years+ - NCT07197723Recruiting
Study of decision making about prostate cancer risk
This study looks at how men with a BRCA1/2 gene change make decisions about their health and prostate cancer risk. Participants will fill out surveys to help researchers understand these choices.
New York, New YorkAges 45–70 - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
New Hyde Park, New YorkAges 18 years+ - NCT06549465RecruitingPhase 2
Ac-225 rosopatamab for PSMA-positive castration-resistant prostate cancer
This trial tests a radioactive drug (Ac-225 rosopatamab tetraxetan) that targets a protein called PSMA on prostate cancer cells. It is for patients whose cancer has stopped responding to hormone therapy and has spread to other parts of the body.
New York, New YorkAges 18 years+ - NCT05985681RecruitingPhase 1
Testing an HPV vaccine to prevent cancer
This trial tests a new vaccine (RG1-VLP) to see if it can prevent HPV-related cancers. It is for women aged 18 to 60 who have not had an HPV vaccine before.
Staten Island, New YorkAges 18–60
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Memorial Sloan Kettering Commack · 4 studies
- Memorial Sloan Kettering Nassau · 4 studies
- Memorial Sloan Kettering Westchester · 4 studies
- Roswell Park Cancer Institute · 4 studies
- NYU Langone Health · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,365 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.